Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Peposertib + Avelumab +/- Radiotherapy in Advanced Solid Tumors
NCT03724890Phase 1Completed
- Sponsor
- EMD Serono
- Start
- Nov 2018
- Primary completion
- Sep 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of peposertib in solid tumor, sponsored by EMD Serono. Primary endpoints: Number of Participants Who Experienced Dose Limiting Toxicities (DLTs), Area Under the Plasma Concentration-Time Curve From Time Zero to 6 Hour and 1 more. Started Nov 2018; status: completed.
02
Drugs
peposertib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT03724890.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724890.